The vaccine was not used on time due to the suspension of its distribution in April.
American experts are urgently trying to decide on how to deal with millions of doses of the new coronavirus vaccine Johnson & Johnson (J&J), which expires this month. This is stated in an article published in the electronic version of The Wall Street Journal.
According to her sources, “hospitals, state health departments, and federal authorities are hastily deciding how to use” such batches of the drug. “The prospect that so many doses [of the vaccine] will be wasted in the United States when there is an acute shortage of them in developing countries is forcing the administration of [President Joe] Biden to share the stocks,” the article says. At the same time, it emphasizes that it is difficult for the US authorities to use this vaccine in the United States or transfer it to other countries in such a short time.
According to the sources, one of the reasons that the J&J vaccine was not used on time is the suspension of its distribution, which took place in April. US regulators were then investigating whether the drug could cause blood clots in patients.
Among the states that have stocks of nearly expired J&J vaccines are Arkansas, West Virginia, Michigan, Ohio, Oklahoma, and Pennsylvania.
The US Food and Drug Administration in late February approved a request from Janssen, owned by Johnson & Johnson, to register its coronavirus vaccine under an expedited emergency procedure. Janssen has become the third coronavirus vaccine approved for use in the United States. At the same time, for the appearance of immunity, one vaccination is enough, and not two, as in the case of drugs from Moderna, as well as Pfizer and BioNTech.